Company Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Tango Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
7.76 ^USD	-0.13%		+4.02%	-21.62%

Apr. 04	British billionaire Joe Lewis fined $5 million by US judge for insider trading	RE
Apr. 04	Multibillionaire Joe Lewis to face US sentencing for insider trading	RE

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).

Number of employees: 140

Managers	Title	Age	Since
Barbara Weber CEO	Chief Executive Officer	67	17-02-28
Daniella Beckman DFI	Director of Finance/CFO	45	16-09-30
Jannik Andersen CTO	Chief Tech/Sci/R&D Officer	-	18-12-31
Adam Crystal CTO	Chief Tech/Sci/R&D Officer	47	23-02-26
Samy Tadros PRN	Corporate Officer/Principal	-	-
John Ross HRO	Human Resources Officer	-	20-03-31
Douglas John Barry LAW	General Counsel	54	21-07-31

Members of the board	Title	Age	Since
Alexis Borisy CHM	Chairman	52	16-12-31
Mace Rothenberg BRD	Director/Board Member	67	21-02-28
Barbara Weber CEO	Chief Executive Officer	67	17-02-28
Lesley Calhoun BRD	Director/Board Member	58	21-02-28
Malte Peters BRD	Director/Board Member	61	18-08-31
John Ketchum BRD	Director/Board Member	-	23-08-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	106,718,315	91,186,993 ( 85.45 %)	0	85.45 %

Name	Equities	%	Valuation
Third Rock Ventures LLC 17.99 %	19,201,475	17.99 %	152 M $
EcoR1 Capital, LLC 12.49 %	13,330,736	12.49 %	106 M $
Fidelity Management & Research Co. LLC 9.171 %	9,787,350	9.171 %	78 M $
Boxer Capital LLC 7.683 %	8,198,642	7.683 %	65 M $
BCTG Holdings LLC 6.549 %	6,988,450	6.549 %	55 M $
Nextech Invest AG 5.186 %	5,533,980	5.186 %	44 M $
Southpoint Capital Advisors LP 4.945 %	5,276,699	4.945 %	42 M $
Southpoint Capital Advisors LP 4.945 %	5,276,699	4.945 %	42 M $
GILEAD SCIENCES, INC. 4.549 %	4,854,443	4.549 %	39 M $
BlackRock Advisors LLC 3.418 %	3,647,371	3.418 %	29 M $

Tango Therapeutics, Inc.

201 Brookline Avenue Suite 901

02215, Boston

http://www.tangotx.com

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.76 USD

Average target price

17.57 USD

Spread / Average Target

+126.44%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
TANGO THERAPEUTICS, INC.	-21.62%	828M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.96%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research